Group 1 - The Hong Kong pharmaceutical ETF (159718.SZ) experienced a decline of 2.27% with a premium of 0.24%, despite a net subscription of 9 million during the day [1] - Among the constituent stocks, Stone Four Pharmaceutical Group (02005) led with a gain of 5.19%, while the biggest loser was Shiyao Group (01093) with a drop of 6.84% [1] Group 2 - Innovent Biologics is collaborating with Takeda Pharmaceutical to develop IBI363, with a development cost sharing of 40/60, and a maximum revenue-sharing ratio in double digits [2] - The collaboration includes an upfront payment of $1.2 billion, which consists of a $100 million strategic investment, and potential milestone payments of up to $10.2 billion [2] - The market has seen a significant adjustment in innovative drugs over the past three months, but expectations have lowered, indicating potential for future catalysts [2] Group 3 - The innovative drug sector is viewed as a long-term industry trend, with a dual cycle of international expansion and domestic revenue growth, indicating an unstoppable upward trend [3] - The Hong Kong pharmaceutical ETF is a balanced composition that includes innovative drugs, CXO, internet healthcare, and innovative medical devices, serving as a convenient standardized tool for investors [3]

Market Overview - The market opened lower and experienced low-volume fluctuations, with Hong Kong pharmaceutical stocks declining due to market sentiment despite positive news regarding overseas expansion [1] - The Hong Kong Stock Connect Innovation Drug ETF (159570) fell over 2%, with a trading volume exceeding 1.6 billion yuan during the session [1] - As of October 21, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) exceeded 20.9 billion yuan, maintaining a leading position in scale and liquidity among peers [1] Strategic Collaborations - Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical to accelerate the development of its next-generation IO and ADC therapies, including two late-stage candidates and one early-stage project [3] - The collaboration includes an upfront payment of 1.2 billion USD, with potential milestone payments totaling up to 10.2 billion USD, bringing the total deal value to a maximum of 11.4 billion USD [3] Business Development (BD) Trends - A surge in business development activities was noted, with five BD announcements totaling 4.266 billion USD made on October 16 and 17 alone [4] - Major companies involved include Hansoh Pharmaceutical, Prigen, and others, with upfront payments ranging from 0.07 billion to 1.2 billion USD [4] - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw mixed performance among its constituent stocks, with notable declines in several companies despite positive news for Innovent Biologics [4] Industry Insights - According to Huaxin Securities, the pace of outbound licensing for innovative drugs has resumed, with 93 transactions recorded by August 2025, accounting for 32% of global transactions [6] - The total upfront payments for these transactions reached 4.3 billion USD, exceeding the total for the previous year and expected to set a new high in nearly a decade [6] - The report indicates that multinational corporations (MNCs) continue to favor early-stage assets from China, particularly in hot areas like bispecific antibodies and ADCs [7] Future Outlook - The fourth quarter is expected to see concentrated BD activities, particularly with the ESMO conference and upcoming quarterly reports [7] - The trend of BD transactions is anticipated to continue as MNCs seek to fill revenue gaps from patent expirations of blockbuster products [7] - The performance of the Hong Kong Stock Connect Innovation Drug ETF (159570) has shown significant growth, with a year-to-date increase of over 109% [9]

Investment Rating - The report maintains a positive outlook on the innovative drug and medical device industry, highlighting key targets for investment [5][24]. Core Insights - The innovative drug sector is experiencing high growth, with a focus on companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. The report emphasizes the potential for value re-evaluation in these firms [5][24]. - Recent business development (BD) deals in the innovative drug sector are expected to catalyze market activity, with notable transactions including Jiangsu Heng Rui Medicine's agreement with Kite for a $1.20 billion upfront payment, potentially reaching $15.20 billion in total [5][24]. - The A-share pharmaceutical sector underperformed the broader market in the third week of October 2025, with the Shanghai Composite Index falling by 1.5% and the SW Biopharma index declining by 2.5% [7][18]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Medical Devices - The report emphasizes the high growth potential in innovative drugs, with key investment targets including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. Related targets include CSPC Innovation Pharmaceutical [5][24]. 2. A-Share Pharmaceutical Sector Performance - In the third week of October 2025, the A-share pharmaceutical sector saw a decline of 2.5%, underperforming the Shanghai Composite Index, which fell by 1.5%. The report notes that the sector's premium relative to all A-shares is currently at a normal level, with a relative premium rate of 74.5% [7][14][21]. 3. Hong Kong and U.S. Pharmaceutical Sector Performance - The report indicates that the Hong Kong and U.S. pharmaceutical sectors also underperformed, with the Hang Seng Healthcare index dropping by 5.8% and the S&P 500 Healthcare index increasing by only 0.7% during the same period [18][24].

Report Summary 1. Industry Investment Rating There is no information provided about the report's industry investment rating. 2. Core Viewpoints - The market for mineral supplements is expected to continue expanding due to increased consumer health awareness, a maturing consumption concept, and policy catalysts in the silver economy [4]. - The industry is evolving from basic nutrition supplementation to more precise and functional demands, with consumers becoming more rational in their choices [10]. - Innovation in dosage forms and absorption optimization, as well as the integration of green and sustainable concepts, are becoming key factors in the industry's development [28][29]. 3. Summary by Directory Market Background - Mineral supplements are a type of nutrient - supplement health food. The calcium - supplement market is leading, and the market for health foods is expected to grow [4][5]. - The industry has gone through a startup period (1981 - 1990), a formation period (1991 - 2000), an adjustment period (2001 - 2010), a development period (2011 - 2020), and a high - quality growth period (2021 - present) [6][7]. Market Status - Market Scale: From 2019 - 2023, the market size grew from RMB 196.365 billion to RMB 212.434 billion with a CAGR of 1.99%. It is expected to grow from RMB 218.4 billion to RMB 242.241 billion from 2024 - 2028 with a CAGR of 2.62% [8]. - Market Supply: The supply side shows structural differentiation and innovation. Upstream focuses on scale and quality control, while mid - stream faces challenges of homogenization and technology upgrading. Innovation focuses on improving bio - availability and consumer experience [9]. - Market Demand: Demand is shifting from basic nutrition to precise functional needs. Consumers choose supplements based on specific life stages and health problems [10]. Market Competition - Market Evaluation Dimensions: Companies are evaluated based on growth potential, innovation ability, cost control, and sales cost management efficiency [12][13][14][15]. - Market Competition Pattern: The industry has three echelons. The first echelon includes Lily Group and Harbin Pharmaceutical Group; the second includes Conba and Tongrentang; the third includes Yiling Pharmaceutical [16]. - Ten Brand Recommendations: Brands such as Lily Group, China Resources Sanjiu, and Shijiazhuang Pharmaceutical Group are recommended for their unique advantages in product customization, brand reputation, and raw - material control [17][18][19]. Development Trends - Precision and Functionality: The market is moving towards customized solutions for specific groups and functions, promoting value - based competition [27]. - Dosage Form Innovation and Absorption Optimization: New technologies are used to improve absorption and develop new dosage forms, enhancing compliance [28]. - Green and Sustainable Development: The industry is integrating sustainable concepts throughout the value chain, from raw materials to packaging [29].

来源：新浪基金 10月21日，港股通创新药板块震荡回暖，100%创新药研发标的——港股通创新药ETF（520880）午后 稳定涨势，场内收涨1.21%终结两连跌。成份股荣昌生物、云顶新耀涨超4%，权重股石药集团、翰森制 药跌1%有所拖累。 【创新药"新势力"——港股通创新药ETF（520880）：纯正创新药，聚焦真龙头，港股高弹性】 港股通创新药ETF（520880）被动跟踪恒生港股通创新药精选指数，该指数完全不含CXO，100%布局 创新药研发类公司，超7成仓位押注大市值创新药龙头，是精准表征创新药硬核力量的纯正创新药指 数。场外投资者可关注其联接基金：025221。 | | | 港股通创新药ETF (520880)标的指数 前十成份股权重高达71.63%,龙头优势显著 | | | --- | --- | --- | --- | | 代码 | 简称 | 权重(%) | 总市值(亿港元) | | 6160.HK | 三济神州 | 10.47 | 3.304 | | 1177.HK | 中国生物制药 | 10.01 | 1,527 | | 1093.HK | 石药集团 | 9.58 | 1,080 | | 18 ...

Market Overview - A-shares continued to rise strongly, with over 4,600 stocks closing in the green, and the Shanghai Composite Index increasing by 1.36% to surpass 3,900 points [1] - The ChiNext Index led the gains with a rise of 3.02%, while the Double Innovation Leading ETF surged by 4.28% [1] - Market sentiment showed significant improvement, with total trading volume reaching 1.89 trillion yuan [1] Sector Performance - The optical module sector experienced a strong rally, with Zhongji Xuchuang rising over 9%, nearing historical highs [3] - The AI-themed ETF, Huabao (159363), saw a substantial increase of 5.59%, recovering both the 10-day and 20-day moving averages, with a trading volume of 1.12 billion yuan [1][5] - The fruit chain concept also performed well, with the electronic ETF (515260) climbing by 4% during the session [1] Key Stocks - Zhongji Xuchuang recorded a five-day increase of over 27%, while other stocks in the optical module sector, such as Xinyisheng and Lian Te Technology, also saw significant gains [3][4] - The electronic ETF (515260) rose by 3.73%, recovering the 5-day moving average, driven by strong demand from the Apple supply chain [8][10] Investment Trends - Analysts suggest that the market style may be shifting, with a potential weakening of the dividend asset focus as technology stocks leverage a "window period" for recovery [3] - The demand for optical modules is expected to grow significantly, with projections indicating a rise in shipments from 800 million to over 2 billion units by 2026 [7] - The performance of the electronic sector is bolstered by the strong sales of the iPhone 17 series, which outperformed the iPhone 16 by 14% in the first ten days of sales [10][12] ETF Insights - The largest and most liquid AI-themed ETF (159363) has a recent scale exceeding 3.4 billion yuan, with an average daily trading volume of over 800 million yuan [7] - The electronic ETF (515260) has a significant weight in the Apple supply chain, with 43.43% of its components linked to Apple [10][12] - The Hong Kong Innovation Drug ETF (520880) showed signs of recovery, with a 1.21% increase, indicating strong buying interest [15]

Core Viewpoint - The A-share and Hong Kong stock markets have experienced significant gains, with the Hong Kong Stock Connect Innovative Drug ETF (159570) seeing a nearly 2% increase and a trading volume approaching 2 billion yuan, indicating strong investor interest and liquidity in the innovative drug sector [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has a current scale exceeding 21 billion yuan, leading its peers in both scale and liquidity [1]. - As of October 20, the ETF has seen a net inflow of over 1.7 billion yuan in the past 20 days [1]. - Major stocks within the ETF, such as Innovent Biologics, CanSino Biologics, and 3SBio, have shown positive performance, with increases exceeding 2% [3]. Group 2: Business Development (BD) Trends - The innovative drug sector continues to thrive, with five business development (BD) deals totaling $4.266 billion reported over two days [3]. - Notable transactions include Hansoh Pharmaceutical with a total deal amount of $1.53 billion and Prigen with $1.64 billion [3]. - The total number of license-out transactions in China from January 1 to October 17, 2025, reached 135, with upfront payments totaling $4.976 billion and total deal amounts reaching $102.996 billion, reflecting strong international interest in Chinese innovative drug assets [5]. Group 3: Upcoming Catalysts - The fourth quarter is expected to see an acceleration in BD activities, with a focus on data from the ESMO conference [5]. - Chinese scholars are leading 23 LBA studies at the 2025 ESMO, showcasing various innovative drugs and highlighting China's growing influence in the global pharmaceutical landscape [7]. - The anticipated release of clinical data from the ESMO conference may lead to a revaluation of Chinese innovative drug pipelines and their corresponding stocks [7]. Group 4: Global Pricing Dynamics - Recent agreements between Pfizer and AstraZeneca with the U.S. government on Most Favored Nation (MFN) pricing have exceeded expectations, potentially impacting global sales forecasts for innovative drugs [8][9]. - Pfizer's agreements cover aspects such as pricing for existing and new drugs, direct sales, and tariff exemptions, which could enhance the market potential for innovative drugs [9][10]. - If MFN pricing trends continue, the peak global sales forecast for innovative drugs, including those licensed out from China, may significantly increase [10].

Group 1 - The core viewpoint indicates that the innovative drug sector in Hong Kong is showing clear signs of bottoming out, supported by several factors [1] - BD (Business Development) transactions have started to recover since October, with historical data showing that transactions from October to January account for over 50% of the annual total, and transaction amounts can reach 60% to 70% of the yearly total [1] - Positive data from ESMO (European Society for Medical Oncology) has emerged, with several important clinical studies, such as AK112 and 3SB707, showing promising results, which is expected to catalyze further trading and stock price increases [1] - The valuation of innovative drugs has reached an absolute bottom, with some companies having little room for further decline [1] Group 2 - As of October 21, 2025, the National Securities Hong Kong Stock Connect Innovative Drug Index (987018) shows mixed performance among its constituent stocks, with notable gainers including CloudTop New Drug (01952) up 5.29% and Zai Lab (09688) up 1.80%, while major decliners include Juno Therapeutics-B (02617) down 6.82% [2] - The Hong Kong Innovative Drug ETF (159286) closely tracks the National Securities Hong Kong Stock Connect Innovative Drug Index and has seen a slight increase of 0.22%, with the latest price at 0.93 yuan [2] - As of September 30, 2025, the top ten weighted stocks in the National Securities Hong Kong Stock Connect Innovative Drug Index account for 71.83% of the index, including companies like BeiGene (06160) and Innovent Biologics (09926) [2]

Investment Rating - The report maintains a positive outlook on the health supplement industry, indicating a sustained growth trend in the medium to long term [2][3]. Core Insights - The health supplement market in China is projected to grow from CNY 321.37 billion in 2020 to CNY 415.03 billion by 2024, with a compound annual growth rate (CAGR) of 6.60%, making it the second-largest market globally after the United States [2][3]. - Per capita consumption in China is approximately one-fifth of that in mature markets like Australia, South Korea, and the United States, indicating significant growth potential [3][20]. - The penetration rate among the elderly population (aged 65 and above) in China is only 23.04%, compared to 73.04% in the U.S., suggesting a 2-3 times growth opportunity [3][20]. - The industry is characterized by a diverse range of upstream raw materials, with concentrated production capacity in certain segments, while downstream companies exhibit relatively strong profitability and are accelerating international expansion [3][24]. Summary by Sections Industry Development and Outlook - The health supplement industry in China is expected to maintain a growth trend, with market size projected to reach CNY 447.3 billion by 2029 [16][20]. - The dual-track registration and filing system for health supplements has been implemented, easing industry entry barriers [16][17]. Industry Chain - Upstream: The variety of raw materials includes vitamins, minerals, amino acids, extracts, and probiotics, with some production concentrated among a few key players [24]. - Downstream: Companies often overlap in production and brand marketing, with low sensitivity to cost changes, allowing them to enjoy high added value through premium pricing [3][24][31]. Sales Channels - E-commerce is the primary sales channel, expected to account for 43.9% of sales by 2024, while traditional channels face challenges [4][24]. Key Companies - **Tongrentang**: A leading brand in the VDS segment, focusing on scientific nutrition and maintaining a market share above the industry average [5][32]. - **Jindaiwei**: A company with a full industry chain layout, emphasizing core raw material advantages and international brand localization [9][32]. - **Xianle Health**: A CDMO leader with multi-formulation development capabilities, covering markets in China, the U.S., and Europe [9][32].

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 0.46% on October 20, with a trading volume of 907 million yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 17, 2024, the fund's shares totaled 8.134 billion, with a total size of 6.968 billion yuan, reflecting a significant increase in both shares and size compared to the previous year [1] Fund Performance - The fund has seen a remarkable increase of 1957.27% in shares and 1744.35% in size since December 31, 2023 [1] - The fund's cumulative trading amount over the last 20 trading days reached 27.487 billion yuan, with an average daily trading amount of 1.374 billion yuan [1] - Year-to-date, the cumulative trading amount is 224.063 billion yuan, averaging 1.173 billion yuan per day over 191 trading days [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 71.34% during the management period [2] - The fund's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2]